Cargando…

Power analysis to detect treatment effects in longitudinal clinical trials for Alzheimer's disease

INTRODUCTION: Assessing cognitive and functional changes at the early stage of Alzheimer's disease (AD) and detecting treatment effects in clinical trials for early AD are challenging. METHODS: Under the assumption that transformed versions of the Mini–Mental State Examination, the Clinical Dem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Zhiyue, Muniz-Terrera, Graciela, Tom, Brian D.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590710/ https://www.ncbi.nlm.nih.gov/pubmed/28890916 http://dx.doi.org/10.1016/j.trci.2017.04.007

Ejemplares similares

Mechanisms of motoric cognitive risk—Hypotheses based on a systematic review and meta‐analysis of longitudinal cohort studies of older adults
por: Mullin, Donncha S., et al.
Publicado: (2022)

Preclinical Alzheimer's disease and longitudinal driving decline
por: Roe, Catherine M., et al.
Publicado: (2016)

Development of Written Materials for Participants in an Alzheimer's Disease and Related Dementias Screening Trial
por: Head, Katharine J, et al.
Publicado: (2022)

Measuring informed consent capacity in an Alzheimer's disease clinical trial
por: Guarino, Peter D., et al.
Publicado: (2016)

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials
por: Andrews, J. Scott, et al.
Publicado: (2019)

PSYCHOMETRICS IN THE DEVELOPING OF LONGITUDINAL MEASURES OF FRAILTY
por: Voll, Stacey, et al.
Publicado: (2022)

The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial
por: Burns, Daniel K., et al.
Publicado: (2019)

Sex-specific composite scales for longitudinal studies of incipient Alzheimer’s disease
por: Banks, Sarah J., et al.
Publicado: (2019)

Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2018)

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab
por: Samtani, Mahesh N., et al.
Publicado: (2015)

African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials
por: Zhou, Yan, et al.
Publicado: (2016)

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial
por: Rios‐Romenets, Silvia, et al.
Publicado: (2020)

Self‐reported diabetes is associated with allocentric spatial processing in the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study
por: Gregory, Sarah, et al.
Publicado: (2022)

Hidden three-state survival model for bivariate longitudinal count data
por: van den Hout, Ardo, et al.
Publicado: (2018)

Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease
por: Libiger, Ondrej, et al.
Publicado: (2021)

Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS)
por: Saunders, Tyler S., et al.
Publicado: (2022)

Methods for handling longitudinal outcome processes truncated by dropout and death
por: Wen, Lan, et al.
Publicado: (2018)

Analyses of natural courses of Japanese patients with Alzheimer's disease using placebo data from placebo-controlled, randomized clinical trials: Japanese Study on the Estimation of Clinical course of Alzheimer's disease
por: Watanabe, Mitsunori, et al.
Publicado: (2019)

Participant outcomes and preferences in Alzheimer's disease clinical trials: The electronic Person-Specific Outcome Measure (ePSOM) development program
por: Saunders, Stina, et al.
Publicado: (2018)

Results and insights from a phase I clinical trial of Lomecel‐B for Alzheimer's disease
por: Brody, Mark, et al.
Publicado: (2022)

Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort
por: Ihara, Ryoko, et al.
Publicado: (2018)

Erratum: Methods for handling longitudinal outcome processes truncated by dropout and death
por: Wen, Lan, et al.
Publicado: (2018)

Age‐stratified longitudinal study of Alzheimer's and vascular dementia patients
por: Jørgensen, Isabella Friis, et al.
Publicado: (2020)

The Power in Coming Together
por: Albert, Debra, et al.
Publicado: (2021)

Understanding and predicting the longitudinal course of dementia
por: Melis, René J.F., et al.
Publicado: (2019)

Progranulin mutations in clinical and neuropathological Alzheimer's disease
por: Vardarajan, Badri N., et al.
Publicado: (2022)

Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairment
por: Wang, Guoqiao, et al.
Publicado: (2015)

Differences in the longitudinal change of behaviours related to dementia in long-term care: a growth mixture modelling approach
por: Robitaille, Annie, et al.
Publicado: (2023)

Quantile regression to characterize solanezumab effects in Alzheimer's disease trials
por: Chen, Yun-Fei, et al.
Publicado: (2016)

Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials
por: Xu, Steven X., et al.
Publicado: (2015)

SEX DIFFERENCES AND LONGITUDINAL QUANTILES OF FRAILTY TRAJECTORIES WITH MISSING DATA DUE TO DEATH
por: Marroig, Alejandra, et al.
Publicado: (2022)

The Power of Two:: One Academic-Practice Partnership’s Response to Coronavirus Disease 2019 (COVID-19)
por: Reynolds, Staci, et al.
Publicado: (2021)

Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease
por: Voss, Tiffini, et al.
Publicado: (2018)

A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study
por: Boada, Mercè, et al.
Publicado: (2020)

The costs of developing treatments for Alzheimer's disease: A retrospective exploration
por: Cummings, Jeffrey L., et al.
Publicado: (2021)

Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease
por: Maher-Edwards, Gareth, et al.
Publicado: (2015)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Rates of longitudinal change in (18)F‐flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease
por: Phillips, Jeffrey S., et al.
Publicado: (2021)

Harnessing the power of microphysiological systems for COVID-19 research
por: Kleinstreuer, Nicole, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_em9d2emisj42afaa8agaijp7rt